IL159150A0 - Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket - Google Patents

Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket

Info

Publication number
IL159150A0
IL159150A0 IL15915002A IL15915002A IL159150A0 IL 159150 A0 IL159150 A0 IL 159150A0 IL 15915002 A IL15915002 A IL 15915002A IL 15915002 A IL15915002 A IL 15915002A IL 159150 A0 IL159150 A0 IL 159150A0
Authority
IL
Israel
Prior art keywords
inhibitor
tad
hpv
complex
binding pocket
Prior art date
Application number
IL15915002A
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of IL159150A0 publication Critical patent/IL159150A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/12Keratolytics, e.g. wart or anti-corn preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2299/00Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/20011Papillomaviridae
    • C12N2710/20022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Laminated Bodies (AREA)
IL15915002A 2001-07-12 2002-07-12 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket IL159150A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30441201P 2001-07-12 2001-07-12
PCT/CA2002/001058 WO2003006495A2 (fr) 2001-07-12 2002-07-12 Co-cristal de domaine/d'inhibiteur de transactivation de papillomavirus e2 humain, et coordonnees de radiographie definissant la poche de liaison avec l'inhibiteur

Publications (1)

Publication Number Publication Date
IL159150A0 true IL159150A0 (en) 2004-06-01

Family

ID=23176405

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15915002A IL159150A0 (en) 2001-07-12 2002-07-12 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket
IL159150A IL159150A (en) 2001-07-12 2003-12-02 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and method for its production

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL159150A IL159150A (en) 2001-07-12 2003-12-02 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and method for its production

Country Status (14)

Country Link
US (1) US7167801B2 (fr)
EP (2) EP1409525B1 (fr)
JP (1) JP4602665B2 (fr)
AT (2) ATE343588T1 (fr)
AU (1) AU2002317122B2 (fr)
CA (1) CA2448482C (fr)
DE (2) DE60236114D1 (fr)
DK (2) DK1409525T3 (fr)
ES (2) ES2274051T3 (fr)
HU (1) HUP0402069A3 (fr)
IL (2) IL159150A0 (fr)
MX (1) MXPA04000271A (fr)
NZ (1) NZ531068A (fr)
WO (1) WO2003006495A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1627323A4 (fr) * 2003-05-06 2008-04-09 New Century Pharmaceuticals Sites de fixation sur l'albumine pour l'evaluation d'interactions medicamenteuses ou la mise au point de medicaments en fonction de leur proprietes de liaison a l'albumine
CA2526675A1 (fr) * 2003-05-26 2004-12-02 Biotie Therapies Corporation Vap-1 cristalline et ses utilisations
CA2585115A1 (fr) * 2003-11-03 2005-05-12 New Century Pharmaceuticals, Inc. Sites de liaison a l'albumine permettant d'evaluer des interactions medicamenteuses et procedes d'evaluation ou de conception de medicaments fondes sur les proprietes de liaison a l'albumine de ces derniers
US20090118301A1 (en) * 2007-11-02 2009-05-07 Arbor Vita Corporation Compositions and Methods for Treating Cancer
CN112891520A (zh) * 2021-04-13 2021-06-04 吉林省国大生物工程有限公司 一种预防和控制人乳头瘤病毒感染(hpv)的活性生物蛋白的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671808B2 (en) 1991-10-11 1996-09-12 Chiron Corporation Methods and compositions for identifying inhibitors of papilloma virus replication
US6306580B1 (en) 1998-05-01 2001-10-23 Boehringer Ingelheim (Canada) Ltd. Preparation of human papillomavirus E1 having helicase activity and method therefor
ATE235509T1 (de) 1998-06-30 2003-04-15 Deutsches Krebsforsch Peptide zur inhibition von hpv e7 proteinen
WO2000075182A1 (fr) * 1999-06-04 2000-12-14 Akira Kaji Cristal de proteine du facteur de recyclage ribosomique (rrf) et son application sur la base de donnees de structure tridimensionnelles provenant du cristal
GB9921938D0 (en) 1999-09-17 1999-11-17 Univ York Target for antiviral therapy
JP2003515324A (ja) * 1999-11-16 2003-05-07 バーテックス ファーマシューティカルズ インコーポレイテッド カスパーゼ−7を含む結晶化可能な組成物
MXPA03005479A (es) 2000-12-18 2004-05-31 Boehringer Ingelheim Ca Ltd Inhibidores del virus de papiloma.

Also Published As

Publication number Publication date
AU2002317122B2 (en) 2007-03-15
ATE465414T1 (de) 2010-05-15
DK1695980T3 (da) 2010-08-02
DE60215658D1 (de) 2006-12-07
DE60215658T2 (de) 2007-12-27
EP1695980A2 (fr) 2006-08-30
HUP0402069A3 (en) 2012-09-28
US20030082769A1 (en) 2003-05-01
ES2342309T3 (es) 2010-07-05
MXPA04000271A (es) 2005-03-07
EP1409525A2 (fr) 2004-04-21
IL159150A (en) 2009-09-01
WO2003006495A2 (fr) 2003-01-23
DK1409525T3 (da) 2007-02-05
HUP0402069A2 (hu) 2005-01-28
EP1409525B1 (fr) 2006-10-25
CA2448482A1 (fr) 2003-01-23
EP1695980A3 (fr) 2006-09-06
CA2448482C (fr) 2011-12-06
ES2274051T3 (es) 2007-05-16
WO2003006495A3 (fr) 2003-07-31
JP4602665B2 (ja) 2010-12-22
EP1695980B1 (fr) 2010-04-21
DE60236114D1 (de) 2010-06-02
ATE343588T1 (de) 2006-11-15
US7167801B2 (en) 2007-01-23
NZ531068A (en) 2006-06-30
JP2005512954A (ja) 2005-05-12

Similar Documents

Publication Publication Date Title
AU662142B2 (en) Phenyl amidines derivatives useful as platelet aggregation inhibitors
DE50312257D1 (de) (meth)acrylsaeurekristall und verfahren zur herstellung und aufreinigung von waessriger (meth)acrylsaeure
PL373374A1 (en) Substituted cycloalkyl p1' hepatitis c virus inhibitors
ATE350338T1 (de) Chabazit mit hohem gehalt an siliciumdioxid, dessen synthese und verwendung zur umwandlung von sauerstoffverbindungen zu olefinen
AU2003299519A1 (en) Hepatitis c virus inhibitors
BRPI0410685B8 (pt) processos de purificação do 1,3-propanodiol e composição
ATE234282T1 (de) Polymorphe verbindungen
BR9909358A (pt) Composto, composição farmacêutica, e, processo para prevenção ou alìvio de complicações crÈnicas decorrentes de diabetes melito
PL373398A1 (en) Heterocyclicsulfonamide hepatitis c virus inhibitors
ATE396190T1 (de) Substituierte heteroarylalkansäure und ihre verwendung als inhibitoren der aldose reductase
ATE431340T1 (de) N- (1-benzyl-2-oxo-2- (1-piperazinyl) ethyl) -1- piperidincarboxamid-derivate und verwandte verbindungen als cgrp-antagonisten zur behandlung von kopfschmerzen
CY1106721T1 (el) Μεθοδος παρασκευης υψηλης καθαροτητας περινδοπριλης και ενδιαμεσα χρησιμα στη συνθεση
BR0015836A (pt) Cristal de 4-carboxiamino-2-etil-1,2,3,4-tetra-hidroquinolina como inibidor de cetp
DE69926061D1 (de) Verfahren und zusammensetzungen zur peptidsynthese (t-20)
ATE255124T1 (de) Verfahren zur gewinnung von phytosterinen durch kristallisation aus verminderten mengen methanols
IL159150A0 (en) Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket
DE59002863D1 (de) Lysolecithinderivate zur behandlung von autoimmunerkrankungen.
EA200601641A1 (ru) Кристаллическая композиция, содержащая оксалат эсциталопрама
ATE274513T1 (de) Verbindungen und verfahren zur behandlung von schmerz
Ricci Jr et al. The crystal and molecular structure of bestatin and its implications regarding substrate binding to the active site of leucine aminopeptidase
NZ516235A (en) Method for purification of proteins
TR200503398T1 (tr) Trandolapril'in yeni kristal formları.
ATE174036T1 (de) Prozess und zwischenverbindungen zur herstellung von blaettchen glycoprotein iib/iiia hemmern
ANDERSEN et al. CONFORMATIONAL TRANSITIONS IN DETERGENT TREATED AND MEMBRANE BOUND Ca2+-ATPase FROM SARCOPLASMIC RETICULUM
TH57580B (th) วิธีการผลิตผลึก